Physician profile
David A Gose
NPI 1528040748
$7,092.34
in general payments reported to CMS, 2019-2025
41 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,312 · 2020: $336 · 2021: $1,120 · 2022: $870 · 2023: $1,153 · 2024: $1,141 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,455.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,023.20 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $1,003.33 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $584.10 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $477.19 | 2019-2024 | Veozah |
| Pfizer INC. | $333.82 | 2019-2025 | |
| Abbvie INC. | $311.32 | 2020-2025 | |
| Lilly USA, LLC | $297.49 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $253.31 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $252.18 | 2019-2024 | Farxiga |
| Abbott Laboratories | $251.35 | 2019-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $223.26 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $213.63 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $164.13 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $159.89 | 2019-2024 | Dificid, Gardasil 9, Gardasil |
| Dexcom, INC. | $158.83 | 2022-2025 | Dexcom G6 Transmitter |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.